Pharming Group (PHAR) Competitors $9.10 +0.16 (+1.79%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PHAR vs. PTGX, AMRX, LBPH, LGND, GERN, NAMS, IDYA, CNTA, WVE, and AKROShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Protagonist Therapeutics (PTGX), Amneal Pharmaceuticals (AMRX), Longboard Pharmaceuticals (LBPH), Ligand Pharmaceuticals (LGND), Geron (GERN), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Wave Life Sciences (WVE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical preparations" industry. Pharming Group vs. Protagonist Therapeutics Amneal Pharmaceuticals Longboard Pharmaceuticals Ligand Pharmaceuticals Geron NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Wave Life Sciences Akero Therapeutics Pharming Group (NASDAQ:PHAR) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking. Do insiders and institutionals hold more shares of PHAR or PTGX? 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to PHAR or PTGX? In the previous week, Pharming Group had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 9 mentions for Pharming Group and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.36 beat Pharming Group's score of 0.41 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer PHAR or PTGX? Protagonist Therapeutics received 258 more outperform votes than Pharming Group when rated by MarketBeat users. However, 64.52% of users gave Pharming Group an outperform vote while only 60.83% of users gave Protagonist Therapeutics an outperform vote. CompanyUnderperformOutperformPharming GroupOutperform Votes2064.52% Underperform Votes1135.48% Protagonist TherapeuticsOutperform Votes27860.83% Underperform Votes17939.17% Do analysts prefer PHAR or PTGX? Pharming Group currently has a consensus target price of $27.00, indicating a potential upside of 196.70%. Protagonist Therapeutics has a consensus target price of $53.78, indicating a potential upside of 29.62%. Given Pharming Group's higher probable upside, equities research analysts plainly believe Pharming Group is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, PHAR or PTGX? Pharming Group has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Which has higher valuation & earnings, PHAR or PTGX? Pharming Group has higher earnings, but lower revenue than Protagonist Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$285.75M2.16-$10.55M-$0.26-35.00Protagonist Therapeutics$323.80M7.64-$78.96M$2.6615.60 Is PHAR or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Pharming Group's net margin of -6.09%. Protagonist Therapeutics' return on equity of 34.68% beat Pharming Group's return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-6.09% -7.65% -3.82% Protagonist Therapeutics 52.76%34.68%30.98% SummaryProtagonist Therapeutics beats Pharming Group on 14 of the 18 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$617.30M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-35.0010.5991.3417.19Price / Sales2.16195.381,117.70116.80Price / Cash92.1557.1642.6437.86Price / Book2.795.104.794.78Net Income-$10.55M$151.51M$120.07M$225.60M7 Day Performance1.31%-2.15%-1.90%-1.23%1 Month Performance16.67%-3.14%11.45%3.37%1 Year Performance-20.59%11.50%30.63%16.58% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.7319 of 5 stars$9.10+1.8%$27.00+196.7%-17.4%$617.30M$285.75M-35.00382Analyst ForecastPTGXProtagonist Therapeutics3.5882 of 5 stars$41.33+0.6%$53.78+30.1%+100.0%$2.46B$60M15.44125News CoveragePositive NewsAMRXAmneal Pharmaceuticals2.8823 of 5 stars$7.73-1.3%$10.00+29.4%+47.1%$2.40B$2.68B-11.387,700Analyst DowngradeNews CoveragePositive NewsLBPHLongboard Pharmaceuticals0.659 of 5 stars$59.98+0.0%$59.56-0.7%+986.6%$2.34BN/A-26.9020LGNDLigand Pharmaceuticals4.983 of 5 stars$122.83+5.1%$147.00+19.7%+65.4%$2.32B$152.42M47.4480Analyst RevisionGERNGeron3.8435 of 5 stars$3.78-2.1%$7.15+89.2%+61.6%$2.29B$29.48M-12.06141Short Interest ↓NAMSNewAmsterdam Pharma2.8064 of 5 stars$24.67-0.1%$36.20+46.7%+142.4%$2.28B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3203 of 5 stars$25.88+2.7%$53.67+107.4%-23.7%$2.24B$3.92M-10.8180Analyst ForecastCNTACentessa Pharmaceuticals2.9987 of 5 stars$16.53-0.2%$25.83+56.3%+131.0%$2.18B$6.85M-10.8372Insider TradeWVEWave Life Sciences4.8765 of 5 stars$13.55+0.8%$22.22+64.0%+181.5%$2.07B$53.61M-12.22240AKROAkero Therapeutics4.0824 of 5 stars$29.05+0.6%$46.83+61.2%+36.1%$2.03BN/A-7.7030Insider Trade Related Companies and Tools Related Companies PTGX Competitors AMRX Competitors LBPH Competitors LGND Competitors GERN Competitors NAMS Competitors IDYA Competitors CNTA Competitors WVE Competitors AKRO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PHAR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
